Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Nakase, Taizen ^a   Yoshioka, Shotaroh ^a   Suzuki, Akifumi ^a  

^a RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NORPHENAZONE; DRUG DERIVATIVE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

ADULT; AGED; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; RATING SCALE; TREATMENT OUTCOME; BRAIN INFARCTION; CLINICAL TRIAL; CONVALESCENCE; DAILY LIFE ACTIVITY; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOLOGY; STROKE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPYRINE; BRAIN INFARCTION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; RECOVERY OF FUNCTION; STROKE;

EID: 79953103571     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-39     Document Type: Article

References (25)

1. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF, . American Heart A, American Stroke Association Stroke C, Clinical Cardiology C, Cardiovascular R, Intervention C, Atherosclerotic Peripheral Vascular D, Quality of Care Outcomes in Research Interdisciplinary Working G Guidelines for the early management of adults with ischemic stroke: A guideline from the american heart association/american stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: The american academy of neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38:1655-1711. 10.1161/STROKEAHA.107.181486, 17431204, American Heart A, American Stroke Association Stroke C, Clinical Cardiology C, Cardiovascular R, Intervention C, Atherosclerotic Peripheral Vascular D, Quality of Care Outcomes in Research Interdisciplinary Working G.
2. European Stroke Organisation Executive C, Committee ESOW Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25:457-507. 10.1159/000131083, 18477843, European Stroke Organisation Executive C, Committee ESOW.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, . Investigators E Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329. 10.1056/NEJMoa0804656, 18815396, Investigators E.
4. Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 2008, 9:125-138. 10.1007/s12028-007-9035-x, 18087682.
5. Fisher M. Injuries to the vascular endothelium: Vascular wall and endothelial dysfunction. Rev Neurol Dis 2008, 5(Suppl 1):S4-11.
6. Ginsberg MD. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 2008, 55:363-389. 10.1016/j.neuropharm.2007.12.007, 2631228, 18308347.
7. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV. Stroke therapy academic industry roundtable (stair) recommendations for extended window acute stroke therapy trials. Stroke 2009, 40:2594-2600. 10.1161/STROKEAHA.109.552554, 2761073, 19478212.
8. Green AR, Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: Experimental and clinical studies with nxy-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord 2005, 4:109-118. 10.2174/1568007053544156, 15857295.
9. Edaravone Acute Infarction Study G Effect of a novel free radical scavenger, edaravone (mci-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003, 15:222-229. 10.1159/000069318, 12715790, Edaravone Acute Infarction Study G.
10. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36:2220-2225. 10.1161/01.STR.0000182241.07096.06, 16166574.
11. Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 2010, 1307:22-27. 10.1016/j.brainres.2009.10.026, 2797401, 19840779.
12. Xi H, Akishita M, Nagai K, Yu W, Hasegawa H, Eto M, Kozaki K, Toba K. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Atherosclerosis 2007, 191:281-289. 10.1016/j.atherosclerosis.2006.05.040, 16806227.
13. Banno M, Mizuno T, Kato H, Zhang G, Kawanokuchi J, Wang J, Kuno R, Jin S, Takeuchi H, Suzumura A. The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology 2005, 48:283-290. 10.1016/j.neuropharm.2004.10.002, 15695167.
14. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 1993, 24:35-41.
15. Mitsias PD, Jacobs MA, Hammoud R, Pasnoor M, Santhakumar S, Papamitsakis NI, Soltanian-Zadeh H, Lu M, Chopp M, Patel SC. Multiparametric mri isodata ischemic lesion analysis: Correlation with the clinical neurological deficit and single-parameter mri techniques. Stroke 2002, 33:2839-2844. 10.1161/01.STR.0000043072.76353.7C, 12468779.
16. Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (edo trial). Cerebrovasc Dis 2009, 27:485-492. 10.1159/000210190, 19321945.
17. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U, . Investigators SIT Nxy-059 for the treatment of acute ischemic stroke. N Engl J Med 2007, 357:562-571. 10.1056/NEJMoa070240, 17687131, Investigators SIT.
18. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy?. Expert Opin Pharmacother 2010, 11:1753-1763. 10.1517/14656566.2010.493558, 20491547.
19. Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, Kashiwaba T. Neuroprotective effect of the free radical scavenger mci-186 in patients with cerebral infarction: Clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 1998, 7:315-322. 10.1016/S1052-3057(98)80049-9, 17895107.
20. Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, Ibayashi S, Iida M. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004, 221:11-17. 10.1016/j.jns.2004.03.002, 15178207.
21. Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989, 1:165-211.
22. Kubo K, Nakao S, Jomura S, Sakamoto S, Miyamoto E, Xu Y, Tomimoto H, Inada T, Shingu K. Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. Brain Res 2009, 1279:139-146. 10.1016/j.brainres.2009.04.045, 19410562.
23. Inatomi Y, Takita T, Yonehara T, Fujioka S, Hashimoto Y, Hirano T, Uchino M. Efficacy of edaravone in cardioembolic stroke. Intern Med 2006, 45:253-257. 10.2169/internalmedicine.45.1423, 16595989.
24. Ohta Y, Takamatsu K, Fukushima T, Ikegami S, Takeda I, Ota T, Goto K, Abe K. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med 2009, 48:593-596. 10.2169/internalmedicine.48.1871, 19367054.
25. ClinicalTrials.gov -A service of the U.S. National Institutes of Health. 2010, http://clinicaltrials.gov/ct2/show/NCT00821821